Personalized predictive lung dosimetry by technetium-99m macroaggregated albumin SPECT/CT for yttrium-90 radioembolization
© Kao et al.; licensee Springer 2014
Received: 28 March 2014
Accepted: 11 June 2014
Published: 29 June 2014
For yttrium-90 (90Y) radioembolization, the common practice of assuming a standard 1,000-g lung mass for predictive dosimetry is fundamentally incongruent with the modern philosophy of personalized medicine. We recently developed a technique of personalized predictive lung dosimetry using technetium-99m (99mTc) macroaggregated albumin (MAA) single photon emission computed tomography with integrated CT (SPECT/CT) of the lung as part of our routine dosimetric protocol for 90Y radioembolization. Its rationales are the technical superiority of SPECT/CT over planar scintigraphy, ease and convenience of lung auto-segmentation CT densitovolumetry, and dosimetric advantage of patient-specific lung parenchyma masses.
This is a retrospective study of our pulmonary clinical outcomes and comparison of lung dosimetric accuracy and precision by 99mTc MAA SPECT/CT versus conventional planar methodology. 90Y resin microspheres (SIR-Spheres) were used for radioembolization. Diagnostic CT densitovolumetry was used as a reference for lung parenchyma mass. Pulmonary outcomes were based on follow-up diagnostic CT chest or X-ray.
Thirty patients were analyzed. The mean lung parenchyma mass of our Southeast Asian cohort was 822 ± 103 g standard deviation (95% confidence interval 785 to 859 g). Patient-specific lung parenchyma mass estimation by CT densitovolumetry on 99mTc MAA SPECT/CT is accurate (bias −21.7 g) and moderately precise (95% limits of agreement −194.6 to +151.2 g). Lung mean radiation absorbed doses calculated by 99mTc MAA SPECT/CT and planar methodology are both accurate (bias <0.5 Gy), but 99mTc MAA SPECT/CT offers better precision over planar methodology (95% limits of agreement −1.76 to +2.40 Gy versus −3.48 to +3.31 Gy, respectively). None developed radiomicrosphere pneumonitis when treated up to a lung mean radiation absorbed dose of 18 Gy at a median follow-up of 4.4 months.
Personalized predictive lung dosimetry by 99mTc MAA SPECT/CT is clinically feasible, safe, and more precise than conventional planar methodology for 90Y radioembolization radiation planning.
KeywordsYttrium-90 radioembolization Selective internal radiation therapy Partition model Technetium-99m macroaggregated albumin SPECT/CT CT lung densitovolumetry Lung mass
Radioembolization (RE) is intra-arterial brachytherapy using yttrium-90 (90Y) resin (SIR-Spheres®, Sirtex Medical Limited, North Sydney, New South Wales, Australia) or glass (TheraSphere®, BTG, Ottawa, Ontario, Canada) microspheres for the treatment of inoperable liver malignancies. Radiomicrosphere pneumonitis is a known complication due to hepatopulmonary shunting of 90Y microspheres from arteriovenous shunts within target hepatic arterial territories [-]. The severity of radiomicrosphere lung injury depends on the extent of hepatopulmonary shunting, the radiation absorbed dose, and its pulmonary biodistribution [,,].
For 90Y resin microspheres, the ‘partition model’ is the simplest method of predictive dosimetry to personalize the intended radiation absorbed doses to tumor and non-tumorous liver and lung based on 99mTc macroaggregated albumin (MAA) scintigraphy [,]. For lung dosimetry, a standard mass of 1,000 g is often assumed [] - an assumption which risks under- or overestimation of the lung radiation absorbed dose depending on patient size, pre-existing chronic lung disease, prior lung surgery or irradiation, lung shunt fraction (LSF), or injected 90Y activity. In the modern era of personalized medicine, there is a clinical need to shift away from assumed masses and to embrace patient-specific lung mass estimates for predictive dosimetry in 90Y RE.
For years, CT densitometry has been used by pulmonologists to evaluate lung parenchymal diseases such as emphysema []. Its premise is the approximate linear relationship between radiographic density, expressed in CT numbers (Hounsfield Unit, HU) and physical density (g/cm3) within the range of lung parenchyma []. This linear relationship was found to be consistent across a wide variety of CT scanners []. Hence, lung auto-segmentation CT densitovolumetry provides a simple, rapid, and convenient way of patient-specific lung parenchyma mass estimation.
We previously showed that 99mTc MAA single photon emission computed tomography with integrated CT (SPECT/CT) of the liver can improve the safety and effectiveness of 90Y resin microsphere RE []. This is due its ability for attenuation and scatter correction of 99mTc MAA activity and for volumetric assessment of target arterial territories to improve partition modeling. The next logical step was to expand 99mTc MAA SPECT/CT dosimetry from the abdomen into the lung.
On the basis of the technical superiority of SPECT/CT over planar scintigraphy, ease and convenience of lung auto-segmentation CT densitovolumetry, and dosimetric advantage of using patient-specific lung parenchyma masses, we recently implemented 99mTc MAA SPECT/CT of the lung into our routine dosimetric protocol, in addition to that of the abdomen []. This is a retrospective report of our clinical outcomes, with a detailed comparison of lung dosimetric accuracy and precision by SPECT/CT versus conventional planar methodology.
Institutional review board approval was obtained for the conduct, waiver of informed consent, and publication of this retrospective study (CIRB 2010/781/C, SingHealth, Singapore). This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Personalized predictive lung dosimetry by 99mTc MAA SPECT/CT was recently integrated into our earlier protocol for liver dosimetry []. Our current protocol is now a single, fully SPECT/CT, seamless workflow from the lung to abdomen. For quality assurance of LSF calculation, conventional planar scintigraphy was also performed for each patient. 90Y resin microspheres (SIR-Spheres®, Sirtex Medical Limited, North Sydney, New South Wales, Australia) were used for RE.
Patients were eligible for this study if they have a pre-RE diagnostic CT chest and follow-up chest imaging at any time in the post-RE period. The follow-up chest imaging may either be a diagnostic CT or chest X-ray, and its purpose was to assess for any radiological features suggestive of radiomicrosphere pneumonitis. If both modalities were available, a diagnostic CT was favored over a chest X-ray. Patients enrolled in ongoing RE clinical trials were excluded.
Imaging and reconstruction protocols
Types of CT scanners
All scintigraphy was performed on a Philips Precedence SPECT/CT scanner (Philips Healthcare, Eindhoven, The Netherlands), which has a dual-head gamma camera integrated with a 16-slice multi-detector CT. All scintigraphy were performed within 1 h of 99mTc MAA injection. For planar imaging, anterior and posterior images of the lung and liver were acquired over 120 s each and matrix size 256 × 256. Attenuation and scatter correction was not performed for planar images.
For SPECT acquisition, 128 frames (20 s per frame, angle step of 3°) were acquired over 360° with a 128 × 128 matrix using a low-energy, high-resolution collimator at photopeak 140 ± 10% keV. All patients were imaged from the lung apex to inferior liver edge, covering one or two bed positions depending on the combined lengths of the lung and liver. SPECT images were reconstructed using Astonish software (Philips Healthcare, Eindhoven, The Netherlands), which is an iterative 3D-ordered subset expectation maximization (3D-OSEM) algorithm incorporating corrections for resolution recovery, attenuation, and scatter correction based on the CT attenuation map, three iterations eight subsets and no filters. Non-contrast-enhanced CT was acquired at free breathing at 120 kVp and 50 mAs. CT images were reconstructed using a soft tissue kernel at 3-mm slice thickness, reconstructed field-of-view 60 cm and matrix size 512 × 512.
Phantom evaluation of CT densitometry
As we had no access to suitable lung phantoms, our CT numbers closer to that of lung density were not assessed. For the purposes of this study, it was assumed that the CT phantom results reported by Cheng et al. [] were applicable to our SPECT/CT scanner.
Lung CT densitovolumetry
Lung CT densitovolumetry for both diagnostic CT and SPECT/CT was performed by auto-segmentation using OsiriX software version 5.6 (Pixmeo, Geneva, Switzerland). The aim was to obtain a reasonable estimate of the patient-specific lung parenchyma mass for dosimetry, conceptually superior to the standard 1,000 g assumption. It was not our aim to obtain a patient's true lung parenchyma mass, which remains unknown. Lung parenchyma masses derived by diagnostic CT were used as a reference for comparison against that derived by SPECT/CT.
On diagnostic CT, the entire left and right lung parenchyma were auto-segmented slice by slice from apex to costophrenic recesses using a two-dimensional trans-axial growing algorithm. The lower threshold CT number was fixed at −1,000 HU, while the upper threshold was visually adjusted between −150 and −600 HU to obtain the best segmentation result for each slice. Each trans-axial region-of-interest (ROI) was visually reviewed and manually refined if necessary. The intent was to include all lung parenchyma and to exclude large hilar vessels, proximal bronchial tree, trachea, and large parenchymal scars, in accordance with external beam radiotherapy conventions []. Trans-axial ROIs for the left and right lungs were interpolated separately to compute their respective volumes and mean CT numbers. The latter was applied into Equation 1 to calculate the approximate lung mean densities (g/cm3) for the left and right lungs. The patient-specific lung parenchyma mass was calculated from the product of its volume and lung mean density for both the left and right lungs.
Lung shunt fraction calculation
Planar image analysis was performed using Philips Extended Brilliance Workspace Nuclear Medicine software version 2.0 (Philips Healthcare, Eindhoven, The Netherlands). Planar ROIs were contoured over the left and right lungs and the liver, excluding the mediastinum. Simple background activity correction was performed using a method similar to that described by Jha et al. []. Scatter correction was not performed to be consistent with conventional methodology [,]. Both anterior and posterior images were contoured to obtain geometric means of lung and liver counts.
Due to variable in vivo breakdown of 99mTc MAA, background activity may be present due to free pertechnetate within the blood pool and soft tissue, in addition to scatter. On SPECT/CT, simple lung background activity correction was performed by first estimating the background count density (counts/cm3) using a long cylindrical VOI placed along the left erector spinae muscle in the posterior abdomen. The lung background counts above the exclusion zone were calculated as the product of the background count density and the lung parenchyma tissue volume above the exclusion zone. The lung parenchyma tissue volume (not to be confused with CT lung volume) was estimated as follows: lung parenchyma mass above exclusion zone/1.04, where 1.04 g/cm3 is the assumed physical density of general soft tissue (not be confused with lung mean density estimated from Equation 1). The lung background counts above the exclusion zone were subtracted accordingly to obtain the background-corrected lung counts above the exclusion zone. This was further divided by the CT lung volume above the exclusion zone to obtain the background-corrected lung mean count density (counts/cm3), which we assumed to be representative of the entire lung. The background-corrected counts for the entire lung were calculated as the product of the background-corrected lung mean count density and the total CT lung volume on SPECT/CT. To complete the LSF denominator of Equation 2, background-corrected counts of all target hepatic arterial territories were obtained as previously described for liver SPECT/CT dosimetry [].
Lung mean absorbed dose calculation
For the purposes of this study, the ‘reference Dmean’ (i.e., gold standard) for each patient was assumed to be best approximated by a combination of SPECT/CT LSF and lung parenchyma mass derived by diagnostic CT densitovolumetry. ‘Planar methodology’ refers to conventional Dmean calculation based on planar LSF and the standard 1,000 g assumption. ‘SPECT/CT methodology’ refers to personalized Dmean calculation using SPECT/CT to derive both the LSF and the patient-specific lung parenchyma mass.
Data were assumed to follow a normal distribution and presented in mean ± standard deviation (SD), median, and 95% confidence intervals (CI). Paired two-tailed t test was used to compare the difference between the means of two related datasets; a p value <0.05 was considered statistically significant. Bland-Altman methodology was used to compare two methods of measurement, where the mean difference between the two methods is the bias and represents accuracy, while the 95% limits of agreement (LOA) is the bias ± 1.96 SD and represents precision.
Patient characteristics, injected 90 Y activity, and follow-up chest imaging
Metastatic colon cancer
62.5 ± 11.2; 63.5
58.5 to 66.5; 28 to 80c
Injected 90Y activity (GBq)b
1.65 ± 0.78; 1.44
1.37 to 1.93; 0.50 to 3.62c
Time from pre-RE diagnostic CT chest to 99mTc MAA SPECT/CT (weeks)b
10.4 ± 21.8; 1.9
2.6 to 18.2; 0.3 to 105.3c
Time to follow-up chest imaging (months)b
4.9 ± 3.4; 4.4
3.7 to 6.1; 1.2 to 17.5c
Follow-up chest imaging modality
Diagnostic CT chest
Lung quantification results
Mean ± SD; median; 95%CI; range
Bias ± SD; 95%LOA
Lung mean density (g/cm3)
0.215 ± 0.049; 0.201; 0.197 to 0.232; 0.121 to 0.376
Left lung, compared to right
0.217 ± 0.054; 0.201; 0.197 to 0.236; 0.128 to 0.383
p = 0.44
+0.0019 ± 0.0131; −0.0239 to +0.0276
Mean of both lungs
0.216 ± 0.051; 0.206; 0.197 to 0.234; 0.125 to 0.379
0.291 ± 0.051; 0.289; 0.273 to 0.309; 0.180 to 0.410
Left lung, compared to right
0.306 ± 0.064; 0.310; 0.273 to 0.309; 0.161 to 0.442
p = 0.002
+0.0152 ± 0.0243; −0.0324 to +0.0628
Mean of both lungs, compared to diagnostic CT
0.299 ± 0.056; 0.298; 0.278 to 0.319; 0.171 to 0.417
Lung parenchyma mass (g)
822 ± 103; 809; 785 to 859; 621 to 1,107
828 ± 114; 823; 783 to 874; 621 to 1,107
795 ± 19; 801; 780 to 811; 764 to 812
All patients, compared to diagnostic CT
788 ± 110; 736; 748 to 827; 624 to 1,045
p = 0.19
−21.7 ± 88.2; −194.6 to +151.2
Lung volume (cm3)
3,967 ± 798; 4,049; 3,682 to 4,253; 2,142 to 5,634
SPECT/CT, compared to diagnostic CT
2,749 ± 744; 2,530; 483 to 3,015; 1,698 to 5,199
Lung shunt fraction (%)
5.96 ± 4.59; 4.97; 4.32 to 7.61; 0.98 to 21.71
Planar, compared to SPECT/CT
7.36 ± 4.96; 6.03; 5.58 to 9.14; 2.20 to 25.26
+1.40 ± 1.60; −1.73 to +4.52
Lung Dmean (Gy)
6.16 ± 5.24; 3.64; 4.28 to 8.03; 0.76 to 17.52
Planar, compared to reference
6.07 ± 4.51; 4.75; 4.46 to 7.68; 1.00 to 16.02
p = 0.78
−0.09 ± 1.73; −3.48 to +3.31
SPECT/CT, compared to reference
6.48 ± 5.51; 4.06; 4.51 to 8.45; 0.85 to 18.87
p = 0.11
+0.32 ± 1.06; −1.76 to +2.40
Planar, compared to SPECT/CT
p = 0.27
−0.41 ± 2.00; −4.32 to +3.50
Water phantom studies obtained a mean CT number of water of 8.8712 ± 3.3887 HU (range −6 to 25 HU, VOI 518 cm3). By Equation 1, the calculated physical density of water was 1.0089 ± 0.0034 g/cm3 (range 0.9940 to 1.025). Compared to an expected water density of 1 g/cm3, this result shows a low mean error of +0.9 ± 0.3% for CT densitometry on our SPECT/CT system.
On diagnostic CT, the mean lung mean density was 0.216 ± 0.051 g/cm3 (95% CI 0.197 to 0.234). There was no statistically significant difference between the means of the left versus right lung mean densities (p = 0.44). Bland-Altman analysis showed both the bias and 95% LOA between the left and right lung mean densities to be clinically insignificant (Table 3). Overall, these results provide technical assurance that lung CT densitometry was accurate, precise, and repeatable.
The mean lung volume by SPECT/CT was significantly smaller (p <0.001) than that by diagnostic CT (Table 3). This was an expected finding because SPECT/CT was acquired at free breathing while diagnostic CT was acquired at inspiratory breath-holding.
Lung shunt fraction
Lung mean absorbed dose
When the mean Dmean by planar methodology was directly compared to that by SPECT/CT methodology, we found no statistically significant difference between the two methods (p = 0.27). Bland-Altman analysis showed planar methodology to have a small bias of −0.41 Gy compared to SPECT/CT, which was dosimetrically insignificant. However, its 95% LOA was moderately large, ranging between −4.32 and +3.5 Gy. Overall, these results suggest moderate disagreement between planar and SPECT/CT methodologies for Dmean calculation and, therefore, should not be used interchangeably (Table 3).
Safe and effective partition modeling relies on the accurate input of dosimetric parameters such as tissue masses, tumor-to-normal liver ratio and LSF. We previously showed that 99mTc MAA SPECT/CT of the abdomen can improve partition modeling for the liver []. As an extension of our earlier work, this study clinically validates 99mTc MAA SPECT/CT for personalized predictive lung dosimetry and has provided initial data on its safety, accuracy, and precision.
Our lung CT densitovolumetry results are in keeping with the literature. Rosenblum et al. found the whole-lung mean CT number among 19 subjects under inspiratory breath-holding to be −802 ± 34 HU and among 44 subjects under free breathing to be −734 ± 58 HU []. These figures translate into a mean lung mean density of 0.198 ± 0.034 g/cm3 (95% CI 0.182 to 0.214) by inspiratory breath-hold CT and 0.266 ± 0.058 g/cm3 (95% CI 0.249 to 0.283) by free-breathing CT, comparable to our results. Our study has also found planar LSFs to be slightly overestimated as compared to SPECT/CT LSFs. This observation was consistent with the literature and may be explained by the lack of attenuation and scatter correction in planar scintigraphy [,-].
Our study has shown conventional planar methodology, with its assumption of a standard 1,000 g lung mass, to be dosimetrically accurate, affirming its strong history of clinical safety. However, we found planar methodology to be less precise than SPECT/CT methodology. While our data shows planar methodology to be accurate when analyzed across a cohort, its relative imprecision risks dosimetric uncertainty for patients who fall beyond population norms. Examples are patients with extremes of height, pre-existing chronic lung disease (e.g., emphysema, interstitial lung disease), undergone prior lung surgery or irradiation. Such patients should not be assumed to have ‘standard’ lung masses or lung parenchymal radiobiology and will benefit from personalized predictive lung dosimetry. Its clinical impact is greatest under the paradigm of partition modeling, which relies heavily on dosimetric accuracy and precision for the safe escalation of intended tumor absorbed doses. Furthermore, we have found the mean lung parenchyma mass of our Southeast Asian cohort to be nearly always less than 1,000 g. Ultimately, planar methodology is undesirable from a dosimetric perspective because its assumption of a standard 1,000 g lung mass is fundamentally incongruent with the modern era of personalized medicine.
We found planar methodology to have a dosimetrically insignificant bias of −0.41 Gy compared to SPECT/CT methodology for Dmean calculation. However, its 95% LOA was moderately large (−4.32 to +3.5 Gy) and therefore these two methods cannot be regarded as dosimetrically equivalent. This means that a choice of either method would not be expected to significantly affect lung dosimetry in patients of average anthropometry but may significantly impact those who fall beyond population norms. Although correlations exist across a population between lung parenchyma mass and physical parameters such as age, body weight, or height, modern personalized medicine encourages clinicians to pursue patient-specific measurements for individualized therapeutic guidance. Therefore, we advocate SPECT/CT methodology to be routinely used for lung predictive dosimetry and advise against using planar and SPECT/CT methodologies interchangeably for Dmean calculation.
SPECT/CT methodology overcomes most of the technical limitations of planar methodology and also enables CT densitovolumetry for patient-specific lung parenchymal mass estimation. On the technical issue of SPECT/CT mis-registration due to free breathing, this problem similarly affects planar scintigraphy and therefore should not be regarded as a comparative disadvantage. On the contrary, SPECT/CT can partially overcome this problem using the technique outlined in this report. Respiratory-gated 99mTc MAA SPECT/CT is a promising solution which warrants investigation.
Although our SPECT/CT technique for patient-specific lung parenchyma mass estimation was shown to be accurate, it was only moderately precise. Lung CT densitovolumetry may be affected by many physiological and technical factors such as the phase of respiration [], variations in pulmonary blood flow [], intravenous contrast, CT reconstruction [], and ROI delineation methods. Further research is necessary to improve its precision on SPECT/CT. However, it is important to reiterate that our aim was not to derive a patient's true lung parenchyma mass, which remains unknown, but its reasonable estimate. To this end, we believe our SPECT/CT methodology has served its purpose well.
A limitation of our study was the lack of a true gold standard for Dmean for clinical validation of our SPECT/CT methodology. 99mTc MAA is an imperfect surrogate for 90Y resin microspheres due to slightly dissimilar physical properties []. It is also theoretically possible for LSFs to dynamically change during RE due to progressive microembolization. Therefore, LSFs simulated by 99mTc MAA only give an estimate of the true post-RE LSF. The relative contribution to errors in Dmean due to biophysical and technical inaccuracies from 99mTc MAA and scintigraphic methods are beyond the scope of this study, However, we believe 99mTc MAA SPECT/CT to be feasible for personalized predictive lung dosimetry until superseded by better simulation microspheres (e.g., fluorine-18 resin microspheres []) or imaging modalities (e.g., respiratory-gated 90Y PET/CT []). Another limitation of our study was the assumption of normal distribution for our data for statistical tests of significance. We believe this assumption to be reasonably valid for our sample size of 30 patients.
We have clinically validated our SPECT/CT methodology up to Dmean 18 Gy without radiomicrosphere pulmonary toxicity. This study has also provided early data on the statistical limits of dosimetric uncertainty for Dmean planned by 99mTc MAA, represented by the bias and LOA. This statistical data may guide personalized predictive lung dosimetry in a manner similar to that recently described for the liver [].
Patient-specific lung parenchyma mass estimation by CT densitovolumetry on 99mTc MAA SPECT/CT is accurate and moderately precise. Lung mean radiation absorbed doses calculated by 99mTc MAA SPECT/CT is accurate and offers better precision than planar methodology. An integrated, seamless, and personalized dosimetric workflow by 99mTc MAA SPECT/CT from lung to abdomen is clinically feasible and safe.
We thank the following individuals for contributing to this study: Nadia Chandra, Research Coordinator, Department of Nuclear Medicine and PET, Singapore General Hospital; Doreen Lau Ai Hui and Dr Kei Pin Lin, Department of Diagnostic Radiology, Singapore General Hospital. This study was partially funded by a research grant from Sirtex Medical Singapore.
- Lin M: Radiation pneumonitis caused by yttrium-90 microspheres: radiologic findings. AJR Am J Roentgenol 1994, 162: 1300–1302. 10.2214/ajr.162.6.8191985View ArticlePubMedGoogle Scholar
- Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, Metreweli C, Johnson PJ, Li AK: Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995, 33: 919–924. 10.1016/0360-3016(95)00039-3View ArticlePubMedGoogle Scholar
- Ho S, Lau WY, Leung WT, Chan M, Chan KW, Johnson PJ, Li AK: Arteriovenous shunts in patients with hepatic tumors. J Nucl Med 1997, 38: 1201–1205.PubMedGoogle Scholar
- Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Ibrahim S, Mulcahy MF, Kulik L, Liu DM, Riaz A, Omary RA, Kennedy AS: Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 2008, 31: 431–438. 10.1097/COC.0b013e318168ef65View ArticlePubMedGoogle Scholar
- Wright CL, Werner JD, Tran JM, Gates VL, Rikabi AA, Shah MH, Salem R: Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. J Vasc Interv Radiol 2012, 23: 669–674. 10.1016/j.jvir.2012.01.059View ArticlePubMedGoogle Scholar
- Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ, Li AK: Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 1996, 23: 947–952. 10.1007/BF01084369View ArticlePubMedGoogle Scholar
- Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK: Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997, 24: 293–298.PubMedGoogle Scholar
- SIR-Spheres package insert (CR1507) In ᅟ. Sirtex Medical Limited, North Sydney, NSW, Australia; 2012.
- Guenard H, Diallo MH, Laurent F, Vergeret J: Lung density and lung mass in emphysema. Chest 1992, 102: 198–203. 10.1378/chest.102.1.198View ArticlePubMedGoogle Scholar
- Mull RT: Mass estimates by computed tomography: physical density from CT numbers. AJR Am J Roentgenol 1984, 143: 1101–1104. 10.2214/ajr.143.5.1101View ArticlePubMedGoogle Scholar
- Cheng CW, Zhao L, Wolanski M, Zhao Q, James J, Dikeman K, Mills M, Li M, Srivastava SP, Lu XQ, Das IJ: Comparison of tissue characterization curves for different CT scanners: implication in proton therapy treatment planning. Transl Cancer Res 2012, 1: 236–246.Google Scholar
- Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, Tay KH, Tan BS, Hoe Chow PK, Eng Ng DC, Whatt Goh AS: Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med 2012, 53: 559–566. 10.2967/jnumed.111.097469View ArticlePubMedGoogle Scholar
- Saw CB, Loper A, Komanduri K, Combine T, Huq S, Scicutella C: Determination of CT-to-density conversion relationship for image-based treatment planning systems. Med Dosim 2005, 30: 145–148. 10.1016/j.meddos.2005.05.001View ArticlePubMedGoogle Scholar
- Rosenblum LJ, Mauceri RA, Wellenstein DE, Thomas FD, Bassano DA, Raasch BN, Chamberlain CC, Heitzman ER: Density patterns in the normal lung as determined by computed tomography. Radiology 1980, 137: 409–416.View ArticlePubMedGoogle Scholar
- Drummond GB: Computed tomography and pulmonary measurements. Br J Anaesth 1998, 80: 665–671. 10.1093/bja/80.5.665View ArticlePubMedGoogle Scholar
- Kong FM, Ritter T, Quint DJ, Senan S, Gaspar LE, Komaki RU, Hurkmans CW, Timmerman R, Bezjak A, Bradley JD, Movsas B, Marsh L, Okunieff P, Choy H, Curran WJ Jr: Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys 2011, 81: 1442–1457. 10.1016/j.ijrobp.2010.07.1977PubMed CentralView ArticlePubMedGoogle Scholar
- Jha AK, Zade AA, Rangarajan V, Purandare N, Shah SA, Agrawal A, Kulkarni SS, Shetty N: Comparative analysis of hepatopulmonary shunt obtained from pretherapy 99mTc MAA scintigraphy and post-therapy 90Y Bremsstrahlung imaging in 90Y microsphere therapy. Nucl Med Commun 2012, 33: 486–490. 10.1097/MNM.0b013e328351672dView ArticlePubMedGoogle Scholar
- Yu N, Srinivas SM, Difilippo FP, Shrikanthan S, Levitin A, McLennan G, Spain J, Xia P, Wilkinson A: Lung dose calculation with SPECT/CT for yttrium-90 radioembolization of liver cancer. Int J Radiat Oncol Biol Phys 2013, 85: 834–839. 10.1016/j.ijrobp.2012.06.051View ArticlePubMedGoogle Scholar
- Kolar P, Neuwirth J, Sanda J, Suchanek V, Svata Z, Volejnik J, Pivec M: Analysis of diaphragm movement during tidal breathing and during its activation while breath holding using MRI synchronized with spirometry. Physiol Res 2009, 58: 383–392.PubMedGoogle Scholar
- Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, Brans B, Lambert B, Konijnenberg M, Borson-Chazot F, Tennvall J, Luster M: EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 2011, 38: 1393–1406. 10.1007/s00259-011-1812-2View ArticlePubMedGoogle Scholar
- O'Doherty J, Scuffham J, Hinton P: The importance of scatter correction for the assessment of lung shunting prior to yttrium-90 radioembolization therapy. Nucl Med Commun 2011, 32: 628–634. 10.1097/MNM.0b013e3283463255View ArticlePubMedGoogle Scholar
- Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, Sposito C, Morosi C, Civelli E, Lanocita R, Camerini T, Bampo C, Bhoori S, Seregni E, Marchianò A, Mazzaferro V, Bombardieri E: Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging 2011, 55: 168–197.PubMedGoogle Scholar
- Busse N, Erwin W, Pan T: Effect of CT acquisition parameters on a lung-mass estimation algorithm. J Nucl Med 2013, 54(Suppl 2):214.Google Scholar
- Van de Wiele C, Maes A, Brugman E, D'Asseler Y, De Spiegeleer B, Mees G, Stellamans K: SIRT of liver metastases: physiological and pathophysiological considerations. Eur J Nucl Med Mol Imaging 2012, 39: 1646–1655. 10.1007/s00259-012-2189-6View ArticlePubMedGoogle Scholar
- Selwyn RG, Avila-Rodriguez MA, Converse AK, Hampel JA, Jaskowiak CJ, McDermott JC, Warner TF, Nickles RJ, Thomadsen BR: 18 F-labeled resin microspheres as surrogates for 90Y resin microspheres used in the treatment of hepatic tumors: a radiolabeling and PET validation study. Phys Med Biol 2007, 52: 7397–7408. 10.1088/0031-9155/52/24/013View ArticlePubMedGoogle Scholar
- Mamawan MD, Ong SC, Senupe JM: Post-90Y radioembolization PET/CT scan with respiratory gating using time-of-flight reconstruction. J Nucl Med Technol 2013, 41: 42. 10.2967/jnmt.112.114413View ArticlePubMedGoogle Scholar
- Kao YH: A clinical dosimetric perspective uncovers new evidence and offers new insight in favor of 99mTc macroaggregated albumin for predictive dosimetry in 90Y resin microsphere radioembolization. J Nucl Med 2013, 54: 2191–2192. 10.2967/jnumed.113.128553View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.